Navigation Links
Mutant protein in muscle linked to neuromuscular disorder
Date:4/16/2014

Sometimes known as Kennedy's disease, spinal and bulbar muscular atrophy (SBMA) is a rare inherited neuromuscular disorder characterized by slowly progressive muscle weakness and atrophy. Researchers have long considered it to be essentially an affliction of primary motor neurons the cells in the spinal cord and brainstem that control muscle movement.

But in a new study published in the April 16, 2014 online issue of Neuron, a team of scientists at the University of California, San Diego School of Medicine say novel mouse studies indicate that mutant protein levels in muscle cells, not motor neurons, are fundamentally involved in SBMA, suggesting an alternative and promising new avenue of treatment for a condition that is currently incurable.

SBMA is an X-linked recessive disease that affects only males, though females carrying the defective gene have a 50:50 chance of passing it along to a son. It belongs to a group of diseases, such as Huntington's disease, in which a C-A-G DNA sequence is repeated too many times, resulting in a protein with too many glutamines (an amino acid), causing the diseased protein to misfold and produce harmful consequences for affected cells. Thus far, human clinical trials of treatments to protect against these repeat toxicities have failed.

In the new paper, a team led by principal investigator Albert La Spada, MD, PhD, professor of pediatrics, cellular and molecular medicine, and neurosciences, and the associate director of the Institute for Genomic Medicine at UC San Diego, propose a different therapeutic target. After creating a new mouse model of SBMA, they discovered that skeletal muscle was the site of mutant protein toxicity and that measures which mitigated the protein's influence in muscle suppressed symptoms of SBMA in treated mice, such as weight loss and progressive weakness, and increased survival.

In a related paper, published in the April 16, 2014 online issue of Cell Reports, La Spada and colleagues describe a potential treatment for SBMA. Currently, there is none.

The scientists developed antisense oligonucleotides sequences of synthesized genetic material that suppressed androgen receptor (AR) gene expression in peripheral tissues, but not in the central nervous system. Mutations in the AR gene are the cause of SBMA, a discovery that La Spada made more than 20 years ago while a MD-PhD student.

La Spada said that antisense therapy helped mice modeling SBMA to recover lost muscle weight and strength and extended survival.

"The main points of these papers is that we have identified both a genetic cure and a drug cure for SBMA at least in mice. The goal now is to further develop and refine these ideas so that we can ultimately test them in people," La Spada said.


'/>"/>

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert  

Related biology news :

1. Artificial intelligence helps detect subtle differences in mutant worms
2. Researchers generate a mutant mouse model useful in the treatment of neuromuscular diseases
3. Mutant gene responsible for pigeons head crests
4. Mutant champions save imperiled species from almost-certain extinction
5. Mechanism of mutant histone protein in childhood brain cancer revealed
6. Zebrafish help identify mutant gene in rare muscle disease
7. In odd-looking mutant, clues about how maize plants control stem cell number
8. IU biologists offer clearer picture of how protein machine systems tweak gene expression
9. Making memories: How 1 protein does it
10. Embryonic development protein active in cancer growth
11. More effective method of imaging proteins
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Mutant protein in muscle linked to neuromuscular disorder
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
Breaking Biology News(10 mins):
(Date:5/3/2016)... 3, 2016 The ... Discovery, Gene Expression) Lab-on-a-chip (IVD & POC, ... Diagnostics Centers), Fabrication Technology (Microarrays, Microfluidics) - ... market is expected to reach USD 17.75 ... in 2015, growing at a CAGR of ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... development, skill-building and compliance training platform on mobile devices, today released a new ... Regulatory Requirements for Medical Devices. The course is essential for owners or operators ...
(Date:5/3/2016)... MA (PRWEB) , ... May 03, 2016 , ... In ... number 25 out of the state’s 76 fastest-growing private companies; a small percentage of ... Massachusetts, and ranked organizations on the percent change in revenue from 2012 to 2015. ...
(Date:5/3/2016)... ... May 03, 2016 , ... Leading CEOs from biotech, ... 31st and June 1st at The Four Seasons Hotel Boston. , The Boston ... sciences, offering exclusive access to key decision makers who influence deal making and ...
Breaking Biology Technology: